期刊文献+
共找到765篇文章
< 1 2 39 >
每页显示 20 50 100
Study on the Effects of National Volume-Based Procurement of Chemical Drugs on Chinese Patent Medicines:Lipid-Lowering Drugs as an Example
1
作者 Zhao Yang Xiao Han +5 位作者 Pei Liang Xiaoting Zhao Qiyun Zhu Hui Ye Chao Yang Bin Jiang 《Health Care Science》 2025年第1期14-24,共11页
Background:Atherosclerotic cardiovascular disease remains the leading cause of death worldwide.This study aims to explore the impact of national volume-based procurement(NVBP)on Chinese patent medicines and provide ev... Background:Atherosclerotic cardiovascular disease remains the leading cause of death worldwide.This study aims to explore the impact of national volume-based procurement(NVBP)on Chinese patent medicines and provide evidence for improving policies and promoting rational drug use.Methods:The study was based on data from the China National Health Insurance Agency that spanned January 2019 to December 2020.Descriptive analysis was conducted using volume and expenditure as variables.Interrupted time series analysis was applied to further analyze Chinese patent medicines.Results:The unit prices of atorvastatin and rosuvastatin decreased by 25%-96%,whereas the prices of Zhibitai and Xuezhikang fluctuated slightly.The affordability is measured as the monthly expenditure on treatment divided by the daily wage.After policy implementation,the affordability of atorvastatin and rosuvastatin improved from 0.242 to 0.014 and from 0.247 to 0.019,respectively.The defined daily doses(DDDs)for atorvastatin and rosuvastatin also increased,whereas total expenditures decreased in hospitals of all levels.Both at the national level and at all levels of hospital,the policy had no significant impact on expenditures for Zhibitai and Xuezhikang and their defined daily doses.Conclusions:The NVBP saved costs in the short term by incorporating high-quality,widely used lipid-lowering drugs.Notably,the policy impacted lipid-lowering chemical drugs,whereas Chinese patent medicines remained largely unaffected.Doctors'use of Chinese patent medicines did not decline,highlighting the clinical specificity of these medicines. 展开更多
关键词 Chinese patent medicine health policy lipid-lowering drugs national volume-based procurement
暂未订购
Quantitative Analysis of the Policy of Centralized Drug Procurement Based on PMC Index Model
2
作者 Duan Xiaoxiang Wang Shuling 《Asian Journal of Social Pharmacy》 2025年第3期222-235,共14页
Objective To quantitatively analyze the policy of centralized drug procurement centralized drug procurement in order to provide reference for the subsequent policy formulation and improvement.Methods Text mining metho... Objective To quantitatively analyze the policy of centralized drug procurement centralized drug procurement in order to provide reference for the subsequent policy formulation and improvement.Methods Text mining method was used to process 15 centralized drugs procurement policies issued at the national level during 2015-2022,and a PMC index evaluation model of centralized drug procurement policies was established.Then,15 centralized drug procurement policies were quantitatively analyzed from the overall and comparative perspective through an evaluation model.Results and Conclusion The average PMC index of 15 centralized drug procurement policies was 6.95,which was acceptable on the whole.Among them,eight were excellent and seven were acceptable.As to the first-order variables,the centralized drugs procurement policy still lacks incentives and constraints.The comparative results show that there are differences in the content and structure of policies,but they are strongly related to each other.Chinese centralized drug procurement policy has been basically formed,which is closely related to medical insurance and medical policies.However,it is still necessary to pay attention to the structure of the policy to ensure the elaboration of the policy content. 展开更多
关键词 centralized drug procurement PMC index POLICY quantitative analysis
暂未订购
The Management Practice and Reflection of Centralized Drug Procurement in Hospitals
3
作者 Yuchen Li 《Proceedings of Business and Economic Studies》 2025年第3期54-59,共6页
The centralized procurement of drugs in the medical system is a key link,which not only affects the economic effect of institutions,but also relates to the medical quality and patient safety.In the current era,central... The centralized procurement of drugs in the medical system is a key link,which not only affects the economic effect of institutions,but also relates to the medical quality and patient safety.In the current era,centralized drug procurement in hospitals can meet the needs of most patients;however,the specific steps of the work still need to be optimized.Starting from the level of hospital drug centralized procurement work,this paper discusses the policy background,analyzes the practice of drug centralized procurement in tertiary hospitals,and provides specific work management suggestions,aiming to improve work efficiency and serve as a reference for optimizing subsequent hospital drug centralized procurement work. 展开更多
关键词 Hospital drugs centralized procurement work Management practice Suggestions
暂未订购
Application Value of PDCA in Hospital Centralized Procurement Quality Management
4
作者 WU Guixin 《外文科技期刊数据库(文摘版)医药卫生》 2021年第7期047-049,共5页
Objective: to analyze the application value of PDCA (Plan-do-check-act) management model in hospital centralized procurement quality management. Methods: from January 2019 to June 2020, our hospital began to apply PDC... Objective: to analyze the application value of PDCA (Plan-do-check-act) management model in hospital centralized procurement quality management. Methods: from January 2019 to June 2020, our hospital began to apply PDCA management model to the quality management of hospital centralized procurement. By using the basic process of planning-implementation-inspection-improvement, and establishing and further optimizing the procurement organization at the organizational level, further formulating and revising the procurement system for the procurement system, centralized procurement and organizing bidding at the operational level. Results: through the application of PDCA management mode, the procurement process can be optimized and necessary optimization can be made for the procurement process, with a significant overall effect. Through the application of PDCA, the procurement task was completed to 100%, and the procurement cost was saved by more than 11.70%, while the quality and satisfaction of the hospital demand department to the purchased products reached 99.67%. Conclusion: the application of PDCA management model in hospital centralized procurement is particularly critical to improve the quality of procurement, which can achieve the objectives of saving procurement costs, improving the quality of purchased products and procurement satisfaction. 展开更多
关键词 PDCA management model centralized procurement procurement costs procurement quality procurement
暂未订购
Analysis on the Mode of Centralized Material Procurement of Group City Gas Enterprises
5
作者 CAO Qili 《外文科技期刊数据库(文摘版)经济管理》 2021年第11期121-124,共6页
With the continuous development of the domestic natural gas market and the increasing trend of group operation of city gas enterprises, each large and medium-sized gas group enterprise cannot achieve cost reduction, e... With the continuous development of the domestic natural gas market and the increasing trend of group operation of city gas enterprises, each large and medium-sized gas group enterprise cannot achieve cost reduction, efficiency improvement and market competitiveness without an efficient centralized procurement system. However, the centralized procurement mode of gas enterprises has gradually deepened from the simple bundle procurement to the standardized and scientific centralized procurement supply chain mode. Based on the summary and analysis of the material centralized purchase mode of a medium-sized city gas group in recent ten years, this paper further explores the idea of the construction of centralized purchase supply chain. 展开更多
关键词 city gas group centralized procurement of materials centralized procurement supply chain
原文传递
Strategic Research on Pharmaceutical Enterprises’ Participation in National Drug Centralized Procurement
6
作者 Yang Dianzheng Xu Wenxiu +1 位作者 Qi Yun Yang Yue 《Asian Journal of Social Pharmacy》 2022年第1期15-22,共8页
Objective To study the influence of national drug centralized procurement policy on pharmaceutical enterprises manufacturing generic drugs and original drugs,so as to provide a reference for them to make different str... Objective To study the influence of national drug centralized procurement policy on pharmaceutical enterprises manufacturing generic drugs and original drugs,so as to provide a reference for them to make different strategic choices.Methods Through the literature research on the related policies and the bidding data,the national drug centralized policies were studied systematically.Combined with the bid-winning price and price reduction range of the winning enterprises in the three rounds of centralized procurement,their difficulties,strategic choices and the winning factors were investigated.Besides,a model was established to clarify the optimal price of enterprises in the process of drug procurement.Results and Conclusion The strategic choices of enterprises in participating national drug centralized procurement are influenced by many factors such as the market share of the original varieties,active pharmaceutical ingredients(APIs)and cost.Therefore,corresponding strategies should be formulated according to the characteristics and interests of enterprises. 展开更多
关键词 drug centralized procurement pharmaceutical enterprises GAME STRATEGY
暂未订购
The Establishment of Management Mode of Centralized Procurement
7
作者 CHEN Keren DU Ping 《外文科技期刊数据库(文摘版)经济管理》 2021年第8期052-055,共6页
In order to implement the relevant provisions of the State-owned Assets Supervision and Administration Commission on the benchmarking of procurement management, improve the effectiveness of procurement, reduce procure... In order to implement the relevant provisions of the State-owned Assets Supervision and Administration Commission on the benchmarking of procurement management, improve the effectiveness of procurement, reduce procurement costs and control the risks of integrity in procurement, the Group Company will step by step promote centralized procurement, build a centralized procurement management system for the Group Company, build an information system for centralized procurement management, give full play to the advantages of overall procurement, strengthen implementation supervision, form a sustainable long-term mechanism for centralized procurement, promote the overall improvement of the procurement management capabilities of units at all levels of the Group Company, and organize member units and subordinate units to implement centralized and unified external procurement of materials, projects and services included in the centralized procurement catalog. The Company adheres to the principle of "overall management and control, platform operation, supervision and balance, intensive and efficient", implements the requirements of the Group Company from the aspects of organizational structure and functions, contract signing methods, business processes, data statistics and analysis, supplier management, inspection and supervision, assessment and evaluation, and establishes a centralized procurement management model. The unit and its subordinate units will hand over the items in the centralized procurement catalog to the centralized procurement platform for unified negotiation and procurement, which will bring into play the economies of scale, save procurement costs, simplify procurement process, reduce procurement risks and improve procurement efficiency. 展开更多
关键词 centralized procurement management system signing of contracts supplier management
原文传递
Suggestions on Foreign Pharmaceutical Enterprises Dealing with China’s Drug Centralized Procurement - Taking the First Batch of Implementation Results as an Example
8
作者 Li Yunlong Ning Bowen Yuan Hongmei 《Asian Journal of Social Pharmacy》 2022年第1期23-33,共11页
Objective To analyze the impact of the first batch of centralized drug procurement on foreign pharmaceutical enterprises since the national centralized drug procurement policy has brought great impact on pharmaceutica... Objective To analyze the impact of the first batch of centralized drug procurement on foreign pharmaceutical enterprises since the national centralized drug procurement policy has brought great impact on pharmaceutical market,and put forward some suggestions on their marketing transformation in China.Methods Firstly,the documents of the drug centralized procurement were studied,and then the sales figures before and after the implementation of the policy were retrieved from MiNET.At the same time,the relevant business adjustment information of foreign pharmaceutical enterprises was collected for analysis.Results and Conclusion The sales of related products of foreign pharmaceutical enterprises have dropped sharply,so they have stripped off these products and reduced their staff.It is suggested that foreign pharmaceutical enterprises should adjust the structure of sales team,strengthen the layout of the market in the county,and accelerate the introduction of innovative drugs to cope with centralized drug procurement. 展开更多
关键词 centralized procurement foreign pharmaceutical enterprise drug price MARKETING REFORM
暂未订购
Analysis on the Application of Information Technology in the Centralized Procurement Management of Modern Enterprise Materials
9
作者 MENGXiangsheng 《外文科技期刊数据库(文摘版)经济管理》 2022年第6期017-020,共4页
In the process of production and operation of modern enterprises, material procurement management is a necessary basic link in production. However, due to the limitations of management methods and technical means, inf... In the process of production and operation of modern enterprises, material procurement management is a necessary basic link in production. However, due to the limitations of management methods and technical means, information technology has certain deficiencies in the centralized material procurement management of modern enterprises, which has a relatively intuitive impact on the centralized material procurement management. Therefore, this paper takes the practical application of information technology in the centralized procurement management of modern enterprise materials as the breakthrough point, and fully analyzes the significance of information technology in the production, operation and management of modern enterprises. At the same time, it makes judgment and observation on the practical problems existing in the application of information technology in the centralized procurement management of materials as the main research content, so as to put forward targeted countermeasures and management methods, so as to ensure the orderly development of the centralized procurement management of materials in modern enterprises and lay a solid foundation for the stable development of subsequent enterprises. 展开更多
关键词 information technology modern enterprise centralized procurement management of materials
原文传递
盐酸普拉克索片集采中选仿制药与原研药疗效与安全性的真实世界比较研究 被引量:1
10
作者 王可 王之舟 +3 位作者 邢晓璇 花一鸣 董宪喆 张兰 《中国医院药学杂志》 北大核心 2025年第5期522-528,共7页
目的:比较真实世界下盐酸普拉克索片国家药品集中带量采购中选仿制药和原研药的疗效与安全性。方法:提取2018年7月1日至2023年6月30日首都医科大学宣武医院使用盐酸普拉克索片原研药和仿制药治疗帕金森病或帕金森综合征的门诊患者处方... 目的:比较真实世界下盐酸普拉克索片国家药品集中带量采购中选仿制药和原研药的疗效与安全性。方法:提取2018年7月1日至2023年6月30日首都医科大学宣武医院使用盐酸普拉克索片原研药和仿制药治疗帕金森病或帕金森综合征的门诊患者处方数据。纳入识别期使用原研药或仿制药的患者,入组后每3个月进行1次随访。通过识别整个随访期患者新出现的诊断和伴随用药以及相对时间来识别药品不良事件以比较两组安全性差异。评估有至少4次随访患者入组后1年左旋多巴等效剂量(levodopa equivalent dose,LED)水平随时间的变化程度以比较两组疗效的差异。结果:共纳入1685例患者,其中原研药组750例,315例患者有至少4次随访记录(随访1年及以上);仿制药组935例,197例有至少4次随访记录。两组患者基本特征经倾向性评分1∶1匹配后差异均无统计学意义(P>0.05)。原研药组随访期共发生159例不良事件,仿制药组发生123例不良事件,Kaplan-Meier生存分析及log-rank检验结果显示两组不良事件发生情况差异无统计学意义(P=0.795)。Scheirer-Ray-Hare检验结果显示仿制药和原研药组LED水平随时间的变化程度差异无统计学意义(H=1.538,P=0.820)。结论:盐酸普拉克索片中选仿制药与原研药的疗效与安全性无明显差异。该研究结果需未来开展多中心前瞻性研究加以验证。 展开更多
关键词 普拉克索 集中带量采购 仿制药 疗效 安全性 真实世界
原文传递
基于全国药品使用监测数据的降糖药物利用情况分析 被引量:1
11
作者 曾大勇 王飞羽 +2 位作者 林荣芳 林翠鸿 黄品芳 《中国现代应用药学》 北大核心 2025年第10期1754-1761,共8页
目的系统分析全国及福建地区各级医疗卫生机构降糖药物使用情况和应用趋势,为合理调整降糖药物用药结构及制定相关政策提供参考。方法基于全国47096家医疗卫生机构药品使用监测数据,采用用药频度分析的方法,以用药频度、限定日费用及排... 目的系统分析全国及福建地区各级医疗卫生机构降糖药物使用情况和应用趋势,为合理调整降糖药物用药结构及制定相关政策提供参考。方法基于全国47096家医疗卫生机构药品使用监测数据,采用用药频度分析的方法,以用药频度、限定日费用及排序比等指标分析降糖药物利用情况。结果2021年全国非胰岛素类降糖药物用量占比最大的为二甲双胍(29.90%),其次为磺脲类药物(25.02%)和α-糖苷酶抑制剂(17.16%),基层医疗卫生机构用量占比最大的为磺脲类药物(36.10%)。福建用量占比最大的为磺脲类药物(28.70%)。全国胰岛素类降糖药物用量占比最高的为预混胰岛素(48.10%),其次为长效(26.62%)、短效(13.71%)、速效(9.78%)及中效胰岛素(1.79%)。但3级医院用量占比最高的为长效胰岛素(37.41%)。2021—2023年福建某3级医院用量占比最大的均为二甲双胍,二肽基肽酶Ⅳ抑制剂用量占比大幅增长后下降,葡萄糖共转运蛋白2抑制剂用量占比逐年大幅增长,胰高糖素样肽-1受体激动剂用量增长较少,磺脲类药物用量占比大幅下降后略回升。长效胰岛素用量占比保持平稳,速效胰岛素用量占比逐年增长,而预混胰岛素逐年下降。结论全国、福建降糖药物使用情况与相关指南推荐方案基本一致,国家组织药品集中带量采购惠民政策作用已经凸显,降糖药物日均费用下降显著。循证证据越来越成为临床正确选择药物的重要依据,但还需要重视基层医疗卫生机构降糖药物用药结构的优化。 展开更多
关键词 降糖药物 用药频度 限定日费用 集中带量采购
原文传递
药品集采政策与药企研发行为 被引量:4
12
作者 王少飞 张勇 冯伟忠 《经济问题》 北大核心 2025年第1期91-99,共9页
药品集采政策会加剧医药行业竞争,从而影响医药企业的研发投入。基于药品集采前后三年医药企业的研发专利样本,针对药品集采政策对药企研发行为影响的回归结果表明,集采政策的实施会增加医药企业的研发专利数量,但医药企业所面临的转换... 药品集采政策会加剧医药行业竞争,从而影响医药企业的研发投入。基于药品集采前后三年医药企业的研发专利样本,针对药品集采政策对药企研发行为影响的回归结果表明,集采政策的实施会增加医药企业的研发专利数量,但医药企业所面临的转换成本和集采的预期市场收益,会影响医药企业的研发行为,并进一步影响医药企业的创新效率。因此,要降低医药行业的制度成本,加强医药企业之间的分工合作和并购重组,提升医药企业的创新效率,从而加快完善药品集中采购制度和推动健康中国的政策落实。 展开更多
关键词 药品集采 研发专利 转换成本 预期市场收益
在线阅读 下载PDF
全国药品集采中标药品和中选企业异常探测 被引量:1
13
作者 牛奔 刘玺鲲 +1 位作者 柴语鹃 蚁文洁 《卫生经济研究》 北大核心 2025年第3期55-58,共4页
第九批全国药品集中带量采购共有41种中标药品,其中国家首年支付总额实际值与理想值差额处于异常值范围和临界值范围的各有5种;处于异常值范围的5种中标药品对应的中选企业共30家,其中首年销售额实际值与理想值的差额处于异常值范围的... 第九批全国药品集中带量采购共有41种中标药品,其中国家首年支付总额实际值与理想值差额处于异常值范围和临界值范围的各有5种;处于异常值范围的5种中标药品对应的中选企业共30家,其中首年销售额实际值与理想值的差额处于异常值范围的有14家。对此,可通过构建“0-1”规划模型,加强对中标药品和中选企业的异常探测,对不同支付额范围的中标药品实施差异化监管策略,多部门协调联动,确保全国药品集采的高度公平、透明与合规,在保障公众利益的同时,提升医疗保障体系的整体效能。 展开更多
关键词 药品集中带量采购 “0-1”规划模型 中标药品 中选企业 异常探测
暂未订购
抗高血压药实施国家集中带量采购政策效果分析 被引量:1
14
作者 薛原 万家欢 +1 位作者 穆耕林 杨晨唯 《中国卫生事业管理》 北大核心 2025年第6期637-642,650,共7页
目的:分析国家药品集中采购政策对中选抗高血压药物采购量、采购金额以及日均费用的影响,探究抗高血压药物实施国家药品集中采购政策的效果,以期助力完善抗高血压药物集采相关政策。方法:选取药融云数据库中第五批国家药品集中采购中选... 目的:分析国家药品集中采购政策对中选抗高血压药物采购量、采购金额以及日均费用的影响,探究抗高血压药物实施国家药品集中采购政策的效果,以期助力完善抗高血压药物集采相关政策。方法:选取药融云数据库中第五批国家药品集中采购中选抗高血压药物2019年1季度至2023年4季度的医院采购数据,通过间断序列模型计算分析抗高血压药物集采实施效果。结果:国家集采政策实施后,抗高血压药物市场呈现显著结构性调整:贝那普利中选品种采购量骤增74383.90 Thousands DDDs(P<0.01),非中选品种锐减49962.29 Thousands DDDs(P<0.01);原研药份额从政策前的70%左右显著下降至34%。采购金额方面,中选品种因采购量增加带动金额上升41945.52 Thousands CNY(P<0.01),但日均费用(DDDc)从1.613元显著下降至1.007元(β_(2)=-0.606,P<0.01);非中选品种DDDc仍维持2.11元(β_(0)+β_(2)=2.238-0.126)。而替代药品雷米普利的采购量及采购费用波动性也较大,但政策效果弱于中选药物贝那普利。结论:抗高血压药物实施国家集中带量采购政策效果显著:增加中选药品使用量,优化医生临床用药;降低中选药品费用,提升患者用药可及性与依从性;非中选仿制药及原研药使用量下降,助力国产优质仿制药行业良性发展。应在考虑临床需求、患者用药可及性及企业产能的背景下纳入更多品种进入集采范围,惠及民生。 展开更多
关键词 集中带量采购 抗高血压药 政策效果
暂未订购
基于双断点中断时间序列分析的甘肃省PCI手术冠心病患者住院费用变化趋势研究 被引量:1
15
作者 韩雪梅 康盼 +9 位作者 崔秀芸 陶生鑫 司苗苗 易济琨 马亦晨 马子媛 李婧宜 王星星 苗瑞 张嘉文 《中国循证医学杂志》 北大核心 2025年第3期265-272,共8页
目的分析集采政策实施前、药品集采政策实施后和耗材集采政策实施后患者住院费用的变化,探索集采政策实施成效。方法本研究为回顾性研究,数据来源于甘肃省卫生健康委员会卫生信息统计中心的病案首页数据,共纳入甘肃省2018年1月1日至2022... 目的分析集采政策实施前、药品集采政策实施后和耗材集采政策实施后患者住院费用的变化,探索集采政策实施成效。方法本研究为回顾性研究,数据来源于甘肃省卫生健康委员会卫生信息统计中心的病案首页数据,共纳入甘肃省2018年1月1日至2022年12月31日期间PCI手术冠心病住院患者32938例。采用双断点中断时间序列模型分析集采政策实施不同阶段患者住院费用变化趋势。结果在集采政策实施的三个阶段次均住院总费用分别为46149.49元、46629.12元、28771.76元。药品集中带量采购政策实施时,次均住院总费用、药品费、耗材费、医疗服务费分别即刻下降4.64%、5.62%、18.12%、8.85%、25.28%。药品集中带量采购政策实施后,次均自付费用、治疗费、其他费用仍保持上升趋势,平均每月上升2.23%、1.51%、1.21%。耗材集采政策实施后,次均医疗服务费即刻上升23.75%,次均住院总费用、自付费用、耗材费、治疗费、康复费均呈下降趋势。结论药品集采政策和耗材集采政策的实施有效控制了PCI手术冠心病患者住院费用,患者个人经济负担减轻,但耗材费和次均医疗服务性费用变化幅度较小,未来还需要进一步优化耗材集采政策,完善医疗服务价格补偿机制,提升医疗服务价值。 展开更多
关键词 中断时间序列分析 集中带量采购 住院费用 冠心病 PCI手术
原文传递
市级药品集中采购政策对某三级甲等医院医疗控费及合理用药的影响 被引量:1
16
作者 张磊 刘恋 《中国药业》 2025年第12期10-12,共3页
目的探讨市级药品集中采购(简称集采)政策对医院医疗控费及合理用药的影响。方法收集某三级甲等医院市级药品集采政策实施前(2023年3月至8月)和实施后(2023年9月至2024年2月)第一批市级集采药品使用数据,比较实施前后医院的药品使用情... 目的探讨市级药品集中采购(简称集采)政策对医院医疗控费及合理用药的影响。方法收集某三级甲等医院市级药品集采政策实施前(2023年3月至8月)和实施后(2023年9月至2024年2月)第一批市级集采药品使用数据,比较实施前后医院的药品使用情况、医疗费用及合理用药情况。结果17个中选药品中有10个(58.82%)超额完成任务量;药品单价明显下降,其中降幅超30%的药品有7个(最高达69.57%);5个抗菌药品的次均费用较政策实施前下降(降幅最高达78.29%)。政策实施后临床医师开具相应药品的处方合格率为98.38%,高于实施前的97.50%。结论第一批市级药品集采政策实施后,医院相关药品费用呈下降趋势,对医院医疗成本费用支出和医保控费均起到了积极作用。 展开更多
关键词 疾病诊断相关分组付费 市级药品集中采购 医疗控费 合理用药
暂未订购
基于间断时间序列法分析集采政策对注射用非甾体抗炎药使用的影响
17
作者 汪江涛 蒋慧莲 +4 位作者 叶鸣 方佳 赵磊 朱和平 丁伯平 《中国新药与临床杂志》 北大核心 2025年第6期467-472,共6页
目的分析药品集中带量采购(以下简称“集采”)政策对医疗机构注射用非甾体抗炎药(NSAIDs)使用的影响。方法采用间断时间序列模型分析安徽省芜湖市中医医院2019年3月至2024年6月注射用NSAIDs月度采购量和采购金额的变化情况。结果集采政... 目的分析药品集中带量采购(以下简称“集采”)政策对医疗机构注射用非甾体抗炎药(NSAIDs)使用的影响。方法采用间断时间序列模型分析安徽省芜湖市中医医院2019年3月至2024年6月注射用NSAIDs月度采购量和采购金额的变化情况。结果集采政策实施后,中标和非中标NSAIDs均有不同程度的降价,且中标药品降价幅度较大。政策执行当月,氟比洛芬、帕瑞昔布和酮咯酸氨丁三醇的月采购金额均显著下降(β_(2)<0,P<0.05或P<0.01)。执行集采政策后,帕瑞昔布的月采购量呈上升趋势(β_(1)+β_(3)>0,P<0.01),氟比洛芬、帕瑞昔布和酮咯酸氨丁三醇的月采购金额均呈下降趋势(β_(1)+β_(3)<0)。结论集采后NSAIDs中标品种价格普遍降低,本院的用药结构发生变化,患者的用药负担减轻。采取多元化的采购方式,合理分配中标和非中标药品的采购份额,可以更好地满足临床和患者的差异化用药需求。 展开更多
关键词 药品集中带量采购 间断时间序列 非甾体抗炎药 氟比洛芬 帕瑞昔布 酮咯酸氨丁三醇
原文传递
国家药品集中带量采购中标结果及中标企业规模分析
18
作者 陈珉惺 唐密 +3 位作者 杨燕 吴卿仪 冯旅帆 金春林 《卫生经济研究》 北大核心 2025年第5期78-80,84,共4页
目的:分析九批十轮国家药品集中带量采购中标结果及中标企业规模,为国家药品集中带量采购制度化推进和医药产业可持续发展提供参考依据。方法:采用描述性分析法和关键知情人访谈法,基于官方数据进行定量定性分析。结果:九批十轮国家药... 目的:分析九批十轮国家药品集中带量采购中标结果及中标企业规模,为国家药品集中带量采购制度化推进和医药产业可持续发展提供参考依据。方法:采用描述性分析法和关键知情人访谈法,基于官方数据进行定量定性分析。结果:九批十轮国家药品集中带量采购中,中选品种数、采购金额总体呈上升趋势,药品和企业中标率趋于平稳,中标药品价格平均降幅稳定在50%左右;中标企业规模分析显示,头部与尾部企业中标率呈现“U型”分布,未出现尾部企业以极低价中标的现象。结论:国家药品集中带量采购对药品市场影响深远,中小企业以极低价竞争入局的现象得以遏制,仍需持续发挥政策倒逼企业创新的作用。 展开更多
关键词 国家药品集中带量采购 中标结果 企业规模
暂未订购
循证决策助力医用耗材集采的现状和发展趋势
19
作者 宋旭萍 杨珍珍 +9 位作者 罗棋尹 后亮瑛 李瑞鑫 张亚杰 甘梓萱 葛龙 魏志鹏 李秀霞 沈斐汉 杨克虎 《中国循证医学杂志》 北大核心 2025年第7期843-849,共7页
《“健康中国2030”规划纲要》指出“落实医疗机构药品、耗材采购主体地位,鼓励联合采购”。国家医保局自成立以来,先后牵头组织开展了五批国家高值医用耗材集中带量采购(集采),在全国范围内形成了国家、省级(含省际联盟)及地市(含地市... 《“健康中国2030”规划纲要》指出“落实医疗机构药品、耗材采购主体地位,鼓励联合采购”。国家医保局自成立以来,先后牵头组织开展了五批国家高值医用耗材集中带量采购(集采),在全国范围内形成了国家、省级(含省际联盟)及地市(含地市联盟)协同推进的工作格局。本文阐释了典型国家医用耗材集采现状,梳理了卫生技术评估等循证决策研究证据形式在我国医用耗材集采中的应用。展望未来,卫生技术评估等多种研究证据形式将助力医用耗材集采目录动态调整,构建医用耗材临床使用综合评价指标体系、循证融合人工智能技术进行医用耗材全生命周期管理,将为集采管理与创新注入新动能。 展开更多
关键词 医用耗材 集采 循证决策
原文传递
集中带量采购政策对某三甲医院口服降糖药物使用的影响 被引量:1
20
作者 马祖文 米尔妮萨·苏来曼 《中国医药科学》 2025年第7期74-77,共4页
目的对比分析实施国家集中带量采购(简称集采)政策前后新疆医科大学第五附属医院(本院)口服降糖药物的使用变化。方法收集本院2019年1月至2023年12月口服降糖药物的品种、数量、使用金额,计算片数构成比、用药频度、日均治疗费用等,分... 目的对比分析实施国家集中带量采购(简称集采)政策前后新疆医科大学第五附属医院(本院)口服降糖药物的使用变化。方法收集本院2019年1月至2023年12月口服降糖药物的品种、数量、使用金额,计算片数构成比、用药频度、日均治疗费用等,分析数据变化。结果实施国家集采政策后,本院集采口服降糖药物品种数量占比自2021年起,均超过50%;集采药品价格均明显下降,二甲双胍片、格列美脲、瑞格列奈片和阿卡波糖片单片价格降幅分别达到96.88%、95.38%、89.40%、83.49%;口服降糖药物金额占比逐年下降,2023年占比降至1.58%;口服降糖药物日均治疗费用下降,降幅最明显的是格列美脲和二甲双胍片,分别为97.26%、95.05%;集采口服降糖药物片数构成比逐年上升,2023年达到88.15%。结论国家集采政策的实施,有效降低了口服降糖药物的价格,切实减轻了糖尿病患者用药的经济负担,在临床被广泛使用。 展开更多
关键词 药品集中带量采购 口服降糖药物 使用结构 变化趋势
暂未订购
上一页 1 2 39 下一页 到第
使用帮助 返回顶部